VRC-ZKADNA090-00-VP

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Flaviviral DiseasesFlaviviridae InfectionsFlavivirus InfectionsPrevention of Zika InfectionRNA Virus InfectionsVirus DiseasesZika VirusZika Virus Infection

Phase 1

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

CompletedNCT02996461

National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Zika Infection, Zika-Specific Immune Response

Start: 2016-12-12End: 2019-09-03Updated: 2019-12-17

Phase 2

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

CompletedNCT03110770

National Institute of Allergy and Infectious Diseases (NIAID)Flaviviral Diseases, Flaviviridae Infections, Flavivirus Infections +4

Start: 2017-03-29End: 2019-10-04Updated: 2024-01-31

Related Papers

Differential dengue antibody responses in recipients of a Zika DNA vaccine are governed by dengue immune history

The Journal of Immunology2023-05-01

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

2017-12-05230 citations